3 Domestic Brand Leader, Latin America Generics and Process Chemistry Stocks With a Strong Future Roadmap: Mankind Pharma, Caplin Point Laboratories and Neuland Laboratories

Domestic and export pharma stocks let investors compare three ways of earning from medicines: selling brands at home, selling generics in fast-growing overseas markets and making ingredients for global drug makers. Mankind Pharma, Caplin Point Laboratories and Neuland Laboratories cover a leading domestic brand company, a Latin America focused generics seller and an active ingredient maker.

This list covers three domestic and export pharma stocks with complete current figures: Mankind Pharma, Caplin Point Laboratories and Neuland Laboratories. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Domestic and Export Pharma Stocks?

Domestic and export pharma stocks are listed drug makers that sell branded medicines in India, generics overseas or ingredients to other manufacturers. Their results depend on prescription growth, market access, approvals and plant utilisation.

Domestic and Export Pharma Stocks at a Glance

On valuation, Caplin Point Laboratories trades at a P/E below the industry P/E, while Mankind Pharma and Neuland Laboratories trade above it, which reflects the growth the market already expects. Readers comparing domestic and export pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Domestic and Export Pharma Stocks Have a Strong Roadmap in India?

Domestic and export pharma stocks have a strong roadmap in India because home demand for medicines is growing steadily and Indian firms are widening their reach in emerging and regulated markets.

• Domestic reach. A large field force brings branded products to doctors in smaller towns.
• Emerging markets. Branded generics in Latin America and Africa grow with healthcare access.
• Ingredient demand. Global drug makers rely on dependable Indian suppliers for complex ingredients.

Why Mankind Pharma Features Among These Domestic and Export Pharma Stocks

Among the domestic and export pharma stocks on this list, Mankind Pharma is one of India's largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.

In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%.

Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.

Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

What to watch: Watch the market share in chronic therapies and the integration of acquired brands.

Why Caplin Point Laboratories Features Among These Domestic and Export Pharma Stocks

Among the branded generics shares on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.

The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.

Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore.

Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

What to watch: Follow new US product approvals and currency trends in Latin American markets.

Why Neuland Laboratories Features Among These Domestic and Export Pharma Stocks

Among the three companies on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Mankind Pharma vs Caplin Point Laboratories vs Neuland Laboratories on Key Financials

The table below sets the three domestic and export pharma stocks side by side on revenue, profit and margin, using reported figures.

Neuland Laboratories posts the highest return on equity in this group at 19.4%. Mankind Pharma has the largest FY26 revenue at Rs 14,636 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with domestic and export pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Domestic and Export Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these domestic and export pharma stocks, the main points are: Long-term branded generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Pricing rules. Government limits on essential medicine prices can influence margins.
• Regulatory audits. Plant inspections can affect supply and approvals.
• Customer concentration. Ingredient makers depend on a limited set of large customers.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter domestic and export pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Domestic and Export Pharma Stocks

Domestic and export pharma stocks suit investors who want exposure across the medicine chain. Mankind Pharma, Caplin Point Laboratories and Neuland Laboratories each have a defined strength and clear growth levers. Based on the 20 October 2026 close, Mankind Pharma trades at Rs 2,253.2, Caplin Point Laboratories at Rs 2,258.8 and Neuland Laboratories at Rs 19,220. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these domestic and export pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track domestic and export pharma stocks, set price alerts and get research-backed stock ideas.

What are domestic and export pharma stocks?

Ans. Domestic and export pharma stocks are listed drug makers that sell branded medicines in India, generics overseas or ingredients to other manufacturers. Their results depend on prescription growth, market access, approvals and plant utilisation. This list looks at three of them, Mankind Pharma, Caplin Point Laboratories and Neuland Laboratories, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.

Which domestic and export pharma stocks are covered in this list?

Ans. This list covers Mankind Pharma, Caplin Point Laboratories and Neuland Laboratories. Based on the 20 October 2026 close, Mankind Pharma traded at Rs 2,253.2, Caplin Point Laboratories at Rs 2,258.8 and Neuland Laboratories at Rs 19,220. Their return on equity ranges from 11.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.2% to 21.1%.

Why do domestic and export pharma stocks have a strong future roadmap in India?

Ans. Domestic and export pharma stocks have a strong roadmap in India because home demand for medicines is growing steadily and Indian firms are widening their reach in emerging and regulated markets. The main drivers are as follows. Domestic reach. A large field force brings branded products to doctors in smaller towns. Emerging markets. Branded generics in Latin America and Africa grow with healthcare access. Ingredient demand. Global drug makers rely on dependable Indian suppliers for complex ingredients. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Mankind Pharma performed financially?

Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.

How has Caplin Point Laboratories performed financially?

Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What risks should investors check before buying domestic and export pharma stocks?

Ans. Investors should check a few risks before buying domestic and export pharma stocks. Pricing rules. Government limits on essential medicine prices can influence margins. Regulatory audits. Plant inspections can affect supply and approvals. Customer concentration. Ingredient makers depend on a limited set of large customers. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of domestic and export pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.